ZNF41

Summary

ZNF41 (zinc finger protein 41, HGNC:13107) is a protein-coding gene on chromosome Xp11.3, encoding Zinc finger protein 41 (P51814). May be involved in transcriptional regulation.

This gene encodes a protein that contains KRAB-A and KRAB-B domains multiple zinc finger DNA binding motifs and finger linking regions characteristic of the Kruppel family. An initial study suggested that this gene may be associated with X-linked cognitive disability, but a later study has called this finding into question (PMID:23871722).

Source: NCBI Gene 7592 — RefSeq curated summary.

At a glance

• Gene–disease (curated): non-syndromic X-linked intellectual disability (Limited, GenCC)
• Clinical variants (ClinVar): 137 total
• Dosage sensitivity (ClinGen): haploinsufficiency little evidence, triplosensitivity no evidence
• MANE Select transcript: NM_001324144

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13107
Approved symbol	ZNF41
Name	zinc finger protein 41
Location	Xp11.3
Locus type	gene with protein product
Status	Approved
Aliases	MGC8941, MRX89
Ensembl gene	ENSG00000147124
Ensembl biotype	protein_coding
OMIM	314995
Entrez	7592

Gene structure

Transcript identifiers

Ensembl transcripts: 29 — 28 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000313116, ENST00000377065, ENST00000432977, ENST00000465311, ENST00000684689, ENST00000894174, ENST00000894175, ENST00000894176, ENST00000894177, ENST00000894178, ENST00000894179, ENST00000894180, ENST00000894181, ENST00000894182, ENST00000894183, ENST00000915705, ENST00000915706, ENST00000915707, ENST00000915708, ENST00000968632, ENST00000968633, ENST00000968634, ENST00000968635, ENST00000968636, ENST00000968637, ENST00000968638, ENST00000968639, ENST00000968640, ENST00000968641

RefSeq mRNA: 20 — MANE Select: NM_001324144 NM_001324139, NM_001324140, NM_001324141, NM_001324142, NM_001324143, NM_001324144, NM_001324145, NM_001324147, NM_001324148, NM_001324149, NM_001324150, NM_001324151, NM_001324152, NM_001324153, NM_001324154, NM_001324155, NM_001324156, NM_001324157, NM_007130, NM_153380

CCDS: CCDS14279

Canonical transcript exons

ENST00000684689 — 5 exons

Exon	Start	End
ENSE00003479680	47456272	47456398
ENSE00003626057	47467410	47467760
ENSE00003627117	47455921	47456016
ENSE00003917920	47445178	47449474
ENSE00003922279	47483095	47483222

Expression profiles

Bgee: expression breadth ubiquitous, 179 present calls, max score 82.56.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 6.3103 / max 172.2434, expressed in 1687 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
199088	4.8670	1601
199087	1.4433	786

Top tissues by expression

247 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
muscle of leg	UBERON:0001383	82.56	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.30	gold quality
gastrocnemius	UBERON:0001388	82.21	gold quality
hindlimb stylopod muscle	UBERON:0004252	81.91	gold quality
islet of Langerhans	UBERON:0000006	80.10	gold quality
apex of heart	UBERON:0002098	79.62	gold quality
skeletal muscle organ	UBERON:0014892	79.38	gold quality
cortical plate	UBERON:0005343	79.35	gold quality
rectum	UBERON:0001052	78.57	gold quality
ganglionic eminence	UBERON:0004023	78.39	gold quality
embryo	UBERON:0000922	78.38	gold quality
ventricular zone	UBERON:0003053	78.37	gold quality
leukocyte	CL:0000738	78.35	gold quality
monocyte	CL:0000576	78.33	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.25	silver quality
heart left ventricle	UBERON:0002084	78.01	gold quality
right atrium auricular region	UBERON:0006631	77.50	gold quality
vermiform appendix	UBERON:0001154	77.18	gold quality
smooth muscle tissue	UBERON:0001135	77.17	gold quality
cardiac ventricle	UBERON:0002082	77.12	gold quality
colonic epithelium	UBERON:0000397	77.00	gold quality
calcaneal tendon	UBERON:0003701	76.92	gold quality
cardiac atrium	UBERON:0002081	76.56	gold quality
stromal cell of endometrium	CL:0002255	76.16	gold quality
bone marrow cell	CL:0002092	75.99	gold quality
heart	UBERON:0000948	75.86	gold quality
pancreas	UBERON:0001264	74.98	gold quality
cerebellar hemisphere	UBERON:0002245	74.32	gold quality
granulocyte	CL:0000094	74.30	gold quality
cerebellar cortex	UBERON:0002129	74.22	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.62

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): STAT1

miRNA regulators (miRDB)

87 targeting ZNF41, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-6753-3P	99.93	66.57	637
HSA-MIR-7107-3P	99.93	66.73	627
HSA-MIR-10523-5P	99.91	69.22	2038
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-6499-3P	99.90	66.38	1212
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-448	99.79	72.37	2103
HSA-MIR-548A-3P	99.76	70.58	3524
HSA-MIR-3150A-3P	99.76	64.44	1640
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-5580-3P	99.70	69.41	2052
HSA-MIR-3618	99.69	68.57	1012

Functional genomics

ClinGen dosage: haploinsufficiency 1 (little evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 1)

• ZNF41 is critical for cognitive development (PMID:14628291)

Cross-species orthologs

0 orthologs

Paralogs (176): ZNF195 (ENSG00000005801), ZNF112 (ENSG00000062370), ZNF275 (ENSG00000063587), ZNF37A (ENSG00000075407), ZNF510 (ENSG00000081386), ZNF506 (ENSG00000081665), ZNF268 (ENSG00000090612), MZF1 (ENSG00000099326), ZNF629 (ENSG00000102870), ZNF175 (ENSG00000105497), ZNF85 (ENSG00000105750), ZFP30 (ENSG00000120784), ZNF45 (ENSG00000124459), ZNF391 (ENSG00000124613), ZNF436 (ENSG00000125945), ZNF484 (ENSG00000127081), ZNF835 (ENSG00000127903), ZNF780B (ENSG00000128000), ZSCAN10 (ENSG00000130182), ZNF317 (ENSG00000130803), ZNF331 (ENSG00000130844), ZNF227 (ENSG00000131115), ZNF141 (ENSG00000131127), ZNF132 (ENSG00000131849), ZNF189 (ENSG00000136870), ZIM3 (ENSG00000141946), ZFP14 (ENSG00000142065), ZNF514 (ENSG00000144026), ZNF300 (ENSG00000145908), RBAK (ENSG00000146587), ZNF157 (ENSG00000147117), ZNF182 (ENSG00000147118), ZNF7 (ENSG00000147789), ZNF117 (ENSG00000152926), ZNF221 (ENSG00000159905), ZNF235 (ENSG00000159917), ZNF714 (ENSG00000160352), ZNF577 (ENSG00000161551), ZNF12 (ENSG00000164631), ZNF3 (ENSG00000166526)

Protein

Protein identifiers

Zinc finger protein 41 — P51814 (reviewed: P51814)

All UniProt accessions (2): P51814, B1AQ29

UniProt curated annotations — full annotation on UniProt →

Function. May be involved in transcriptional regulation.

Subcellular location. Nucleus.

Tissue specificity. Expressed in the heart, brain, placenta, lung, liver, skeletal muscle, kidney and pancreas.

Disease relevance. A chromosomal aberration involving ZNF41 has been found in a patient with severe intellectual disability. Translocation t(X;7)(p11.3;q11.21).

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (8)

UniProt ID	Names	Canonical?
P51814-1	1	yes
P51814-2	2
P51814-3	3
P51814-4	4
P51814-5	5
P51814-6	6
P51814-7	7
P51814-8	8

RefSeq proteins (20): NP_001311068, NP_001311069, NP_001311070, NP_001311071, NP_001311072, NP_001311073, NP_001311074, NP_001311076, NP_001311077, NP_001311078, NP_001311079, NP_001311080, NP_001311081, NP_001311082, NP_001311083, NP_001311084, NP_001311085, NP_001311086, NP_009061, NP_700359 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001909	KRAB	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036051	KRAB_dom_sf	Homologous_superfamily
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF01352

UniProt features (34 total): zinc finger region 18, splice variant 6, sequence variant 3, cross-link 2, chain 1, domain 1, region of interest 1, compositionally biased region 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P51814-F1	64.52	0.13

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 120, 647

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-212436	Generic Transcription Pathway

MSigDB gene sets: 48 (showing top): YY1_Q6, KMCATNNWGGA_UNKNOWN, NKX25_01, YY1_01, GCCATNTTG_YY1_Q6, chrXp11, CIITA_TARGET_GENES, CSHL1_TARGET_GENES, E2F5_TARGET_GENES, FEV_TARGET_GENES, HMG20B_TARGET_GENES, SOX3_TARGET_GENES, UBN1_TARGET_GENES, MIR95_5P, MIR627_3P

GO Biological Process (1): regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (4): DNA binding (GO:0003677), zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RNA Polymerase II Transcription	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA-templated transcription	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
nucleic acid binding	1
transition metal ion binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

910 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZNF41	FTSJ1	Q9UET6	843
ZNF41	ZNF385B	Q569K4	836
ZNF41	ARAF	P07557	828
ZNF41	PQBP1	O60828	684
ZNF41	TIMP1	P01033	626
ZNF41	CTSV	O60911	553
ZNF41	PHF8	Q9UPP1	544
ZNF41	TRIM28	Q13263	515
ZNF41	CHST7	Q9NS84	461
ZNF41	CD99	P14209	427
ZNF41	POGZ	Q7Z3K3	405
ZNF41	ARHGEF6	Q15052	400
ZNF41	NXF5	Q9H1B4	400
ZNF41	HSFX1	Q9UBD0	399
ZNF41	OPHN1	O60890	390

IntAct

11 interactions, top by confidence:

A	B	Type	Score
KRTAP10-7	ZNF41	psi-mi:“MI:0915”(physical association)	0.560
FAM9B	ZNF41	psi-mi:“MI:0915”(physical association)	0.560
ZNF41	FAM9B	psi-mi:“MI:0915”(physical association)	0.560
ZNF41	TLX3	psi-mi:“MI:0915”(physical association)	0.370
ZNF41	SMAD2	psi-mi:“MI:0915”(physical association)	0.370
M		psi-mi:“MI:0914”(association)	0.350
ZNF41	NR4A2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (11): FAM9B (Two-hybrid), KRTAP10-7 (Two-hybrid), FAM9B (Two-hybrid), ZNF41 (Two-hybrid), C11orf57 (Two-hybrid), FAM9B (Two-hybrid), RNPS1 (Two-hybrid), ZNF41 (Affinity Capture-RNA), ZNF41 (Affinity Capture-MS), TLX3 (Two-hybrid), ZNF41 (Two-hybrid)

ESM2 similar proteins: A0A087WUV0, A0JNB1, A2VDP4, B2RUI1, P0CG31, P10072, P17025, P17036, P17097, P18733, P51814, Q08ER8, Q09FC8, Q0VGE8, Q14590, Q15937, Q16600, Q2M3X9, Q4V8A8, Q5CZA5, Q5R8G9, Q5RBX0, Q5VIY5, Q68DI1, Q6J6I6, Q6NX49, Q6P1L6, Q6PG37, Q6ZMS4, Q6ZMW2, Q80YP6, Q86UD4, Q86Y25, Q8IZ26, Q8N184, Q8NB42, Q8NEK5, Q8TAF7, Q8TF47, Q8WXB4

Diamond homologs: A0JPL0, A2VDP4, A6QLU5, A6QPT6, A8MQ14, A8MUZ8, A8MWA4, B1APH4, B2RXC5, E9PYI1, E9Q8G5, O75290, O94892, P08042, P0CH99, P0CI00, P17014, P17025, P17030, P17031, P17032, P17098, P21506, P51508, P51523, P51786, P51814, P52736, P52738, Q02525, Q03923, Q03936, Q06730, Q06732, Q0VCB0, Q13401, Q14587, Q16587, Q2M218, Q2M3X9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

137 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	80
Likely benign	15
Benign	11

Top pathogenic / likely-pathogenic (0)

SpliceAI

715 predictions. Top by Δscore:

Variant	Effect	Δscore
X:47456266:GCTTA:G	donor_loss	1.0000
X:47456267:CTTAC:C	donor_loss	1.0000
X:47456270:A:AC	donor_gain	1.0000
X:47456270:AC:A	donor_gain	1.0000
X:47456271:C:CC	donor_gain	1.0000
X:47456271:CC:C	donor_gain	1.0000
X:47456271:CCCA:C	donor_gain	1.0000
X:47456274:A:AC	donor_gain	1.0000
X:47456275:C:CC	donor_gain	1.0000
X:47449470:CTCAC:C	acceptor_gain	0.9900
X:47449472:CAC:C	acceptor_gain	0.9900
X:47449474:CCTAA:C	acceptor_loss	0.9900
X:47449475:C:CA	acceptor_loss	0.9900
X:47456015:CC:C	acceptor_gain	0.9900
X:47456016:CC:C	acceptor_gain	0.9900
X:47456270:ACC:A	donor_gain	0.9900
X:47456271:CCC:C	donor_gain	0.9900
X:47456399:C:CC	acceptor_gain	0.9900
X:47482457:A:AC	donor_gain	0.9900
X:47482457:ACTC:A	donor_gain	0.9900
X:47482458:C:CC	donor_gain	0.9900
X:47482458:CTCC:C	donor_gain	0.9900
X:47482460:C:CA	donor_gain	0.9900
X:47482471:AAGT:A	donor_gain	0.9900
X:47449475:C:CC	acceptor_gain	0.9800
X:47454492:AGT:A	donor_gain	0.9800
X:47456310:T:TA	donor_gain	0.9800
X:47482457:ACT:A	donor_gain	0.9800
X:47482458:CT:C	donor_gain	0.9800
X:47482458:CTC:C	donor_gain	0.9800

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000151085 (X:47478823 C>T), RS1000180152 (X:47449600 T>C), RS1000328433 (X:47469183 C>G,T), RS1000531967 (X:47453717 T>C,G), RS1000702671 (X:47462689 T>C), RS1000762925 (X:47462162 C>T), RS1000789386 (X:47471464 AAAAAG>A), RS1000932343 (X:47471374 G>A,T), RS1000966171 (X:47453973 G>A), RS1000990142 (X:47484794 C>G), RS1001386237 (X:47471769 G>T), RS1001410066 (X:47446905 A>G), RS1001571917 (X:47455986 A>G), RS1001646679 (X:47460406 G>T), RS1001703102 (X:47464835 T>C)

Disease associations

OMIM: gene MIM:314995 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
non-syndromic X-linked intellectual disability	Limited	X-linked

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
non-syndromic X-linked intellectual disability	Disputed	XL

Mondo (2): intellectual disability (MONDO:0001071), non-syndromic X-linked intellectual disability (MONDO:0019181)

Orphanet (1): NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
C564490	Mental Retardation, X-Linked Nonsyndromic (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
TAK-243	increases sumoylation	1
triphenyl phosphate	affects expression	1
sodium arsenite	increases abundance, increases expression	1
ferrous chloride	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
monomethylarsonous acid	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Allergens	affects cotreatment, increases abundance, increases expression	1
Arbutin	decreases expression	1
Arsenic	increases abundance, increases expression	1
Vehicle Emissions	affects cotreatment, increases abundance, increases expression	1
Benzo(a)pyrene	affects methylation	1
Doxorubicin	decreases expression	1
Gallic Acid	decreases expression	1
Hydrogen Peroxide	increases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Urethane	decreases expression	1
Cadmium Chloride	decreases expression	1
Lactic Acid	decreases expression	1
Particulate Matter	affects cotreatment, increases abundance, increases expression	1

Clinical trials (associated diseases)

197 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1
NCT02746614	Not specified	COMPLETED	Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
NCT02836405	Not specified	COMPLETED	TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders